Primary amyloidosis (AL) - Treatment and prognosis

Authors

  • Margarida Ascensão Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Helena Figueiredo Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Maria José Nabais Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Paula Pimenta Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Francisco Parente Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Ana Paiva Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • José Feio Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Borges Alexandrino Serviço de Medicina II dos Hospitais da Universidade de Coimbra
  • Políbio Serra e Silva Serviço de Medicina II dos Hospitais da Universidade de Coimbra

Keywords:

Primary systemic amyloidosis, AL, tre­atment, prognostic, alfa-interferon, chemotherapy

Abstract

Primary amyloidosis (AL) is an entity with a bad prognosis, in which the various therapeutic measu­res have little influence.

The authors present 7 patients with this diagnosis, who were subjected to AL treatment regimes.

The authors comment on the patient's survival, prog­nostic signs and the syndromes present at the time of diagnosis, as well as the symptomatic and functional evolution with the different treatment regimes and the side effects they presented.

Downloads

Download data is not yet available.

References

Gertz MA, Kyle RA. Primary systemic amyloidosis - a diagnostic primer. Mayo Clinic Proc 1989; 641505-1519.

Hawkins PN, Pepys MB. Amyloidosis. ln Malpas JS, Bergsagel DE, Kyle RA (eds.) Myeloma. Oxford; Oxford University Press. 1995;477-506.

Stone MJ Amyloidosis: a final common pathway for protein deposition in tissues. Blood 1990;75:531-545.

Gertz MA, Kyle RA. Phase II trial of recombinant interferon Alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol 1993;44:125-128.

Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neural Neurosurg Psychiatry 1996; 60:655-660.

Soloman A, Wciss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992; 140:629.

Buxhaum J. Mcchanisms of disease: monodonal immunoglobulin deposition. Hematol Oncol Clin North Am 1992; 6:323-345.

Vogelgcsang S, Klipple GL. The many guises of amyloidosis. Postgrad Med 1994; 96:119-127

Parente F. Vieira O, Pimenta P, Alexandrino B, Silva PS. Amiloidose primária - perspectiva terapêutica. Medicina Interna 1995; 2: 97-105

Cohen AS. Amyloidosis. ln Williams (ed). Hematology. New York Me Graw Hill 1990;1148-1157.

Wong CK, Wang WL. Systemic amyloidosis - a report of 19 cases. Dermatology 1994; 189:47-51.

Kyle RA, Greipp PR, O'Fallon M. Primary systemic amyloido­sis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68:220-224.

Kyle RA, Gertz MA. Plimary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45-59.

Gertz MA, Kyle RA. Response of primary hepatic amyloidosis to melphalan and prednison: a case report and review of literature. Mayo Clin Proc 1986;61:218-221.

Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 1994; 24 124-138.

Ge1tz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-262

Plehn JF, Cornwell GG. The amyloidoses. ln: Conn RB (ed). Current diagnosis. 8th ed. Philadelphia; W. B. Saunders Com­pany. 1991;785-789.

Ouston M, Skinner M, Anderson l, Cohen AS. Peripheral neuro­pathy as an early marker of AL amyloidosis. Arch Intern Med 1989; 149:358-360

Stone M. Amyloidosis: a final common pathway for the protein deposition in tissues. Blood 1990; 75(3):531-545.

Cohen H, Lessin L, Rurkholder P Resolution of primary amyloidosis during chemotherapy, studies in a patient with nephro­tic syndrome. Ann Intern Med 1975;82:466-473.

Schwartz R, Cohen J, Shrier L. Therapy of primary amyloidosis with melphalan and prednison. Arch Intern Med 1979;139:1144-1147.

Kyle R, Wagoner R, Holley K.Primary systemic amyloidosis, resolution of nephrotic syndrome with melphalan and pred­nison. Arch Intern Med 1982;146:1445-1447.

Galton DA, Babapulle FB. The management of myelomatosis. Eur J Haematol 1987; 39:385-398.

Gertz MA, Kyle RA. Successful treatment of primary amyloidosis (letter). 'The authors reply. Mayo Clin Pare 1986; 61:835-836.

Hachulla E, Deveaux M, Duquesnoy B, Marchandise X. Carto­ graphie de l'amylose par scintigraphie au composant sérique amyloide P marqué à l'iode 123: mythe ou réalité? Rev Med Interne 1994; 15:238-239.

Hawkins PN. Diagnosis and monitoring of amyloidosis. Baillie­res Clin Rheumatol 1994; 8:635-659.

Maulin L, Hachulla E, Facon T et ai. Évaluation de l'amylose primitive (AL) par scintigraphie au composantsérique amyloide P: du diagnostic au prognostic. Rev Med Interne 1993; 14:%2.

Hawkins PN, Richardson S, MacSweeney JE et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for tu mover and regression. QJ Med 1993; 86:365-374.

Hachulla E, Deveaux M, Duquesnoy B, Marchandise X. Scinti­graphie au composant amyloide P marqué à l'iode 123: une nouvelle méthode d'évaluation de l'amylose. La Presse Médi­cale 1994; 23:348

Kyle RA. Primary systemic amyloidosis.J lntMed 1992; 232:523-524.

Benson MD. Familial amyloidosis. J lnt Med 1992; 232:525-527.

Kyle AR, Gertz MA. Amyloidosis. ln: Lichtenstein LM, Fauci AS. Current therapy in allergy, immunology and rheumatology, 4th ed, Baltimore: B.C Decker 1992;207-210.

Kyle R, Greipp P, Garton J et al. Primary systemic amyloidosis comparison of melphalan/ prednison versus colchicine. Am J Med 1985; 79:708-718

Lévy Y, Deprez D, Sobel A. Traitment de l'amylose AL sans myélome. Ann Med Intern 1988;139:190-193.

Fritz D, Luggen M, Hess E. Unusual longevity in a primary systemic amyloidosis: a 19 year survivor. Am J Med 1989; 86:245-248.

Cohen A, Rubinow A, Anderson J et al. Survival of patients with primary (AL) amyloidosis colchicine treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987; 82:1182-1190

Gilman AG, Rali TW, Nies AS Taylor P (eds). Goodman & Gilman The pharmacological basis of therapeutics, 8th ed, New York; Pergamon Press 1990.

Ravid M, Chen B, Bernheim J, Kedar I. Ascorbic acid-induced regression of amyloidosis in experimental animais. J Exp Path 1985; 66:137-141.

Cohen AS, Jones LA. Advances in amyloidosis. Curr Opin Rheu­matol 1993; 5:62-76.

Laraki R. L'amylose cardiaque - revue générale. Rev Med Inter­ne 1994; 15:257-267.

Fielder K, Durie B. Primary amyloidosis associated with multi­ple myeloma: predictors of successful therapy. Am J Med 1986; 80:413-418.

Additional Files

Published

1997-09-30

How to Cite

1.
Ascensão M, Figueiredo H, Nabais MJ, Pimenta P, Parente F, Paiva A, Feio J, Alexandrino B, Serra e Silva P. Primary amyloidosis (AL) - Treatment and prognosis. RPMI [Internet]. 1997 Sep. 30 [cited 2024 May 19];4(3):150-5. Available from: https://revista.spmi.pt/index.php/rpmi/article/view/2224

Issue

Vol. 4 No. 3 (1997): Julho/ Setembro

Section

Original Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Medicina Interna

Open Access

Most read articles by the same author(s)

<< < 1 2 3 4